Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Recurrence 3Pancreatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Uterine Cervical Neoplasms 1Tracheal Diseases 1Smoking Cessation 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Peritoneal Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphedema 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Positive Esophagogastric Cancer × Combined Modality Therapy × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡